<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.112067</article-id><article-id pub-id-type="publisher-id">ACM-40341</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210200000_77142583.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  恩格列净治疗2型糖尿病患者心脏重构的Meta分析
  Empagliflozin in Patients with Type 2 Diabetes: A Meta-Analysis of Cardiovascular Remodeling
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>欧</surname><given-names>振飞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>商</surname><given-names>玲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>海凌</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>雪娟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院全科医学科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>02</month><year>2021</year></pub-date><volume>11</volume><issue>02</issue><fpage>469</fpage><lpage>475</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨恩格列净对改善2型糖尿病(T2DM)患者左心室重构的疗效。方法：我们在PubMed、EMBASE、Cochrane Library、Web of Science、CNKI数据库、VIP数据库、Wanfang数据库，共7个电子数据库中搜索了在2020年9月30日之前发表的文章，包括中文和英文。我们在分析中纳入了随机对照试验。评价治疗组与对照组左室超声心动图参数平均变化的差异。结果：Meta分析结果显示，LAVI (WMD = −6.29, 95%CI (−10, −2.58)，P &lt; 0.001), E/e′ (WMD = −2.15, 95%CI (−4.08, −0.21), P = 0.003), LVEF (WMD = 3.67, 95%CI (0.59, 6.75), P = 0.02), LVEDV (WMD = −1.99, 95%CI (−26.49, −22.50), P = 0.87), LVESV (WMD = −8.36, 95%CI (−17.36, −0.65), P = 0.07)。结论：恩格列净可显著降低2型糖尿病患者的LAVI和E/e′，改善患者心功能。
    Objective: The purpose of this meta-analysis is to explore the efficacy of empagliflozin in improving left ventricular (LV) remodeling in patients with type 2 diabetes (T2DM). Methods: We searched articles published before September 30, 2020, Language including Chinese and English, in 7 electronic databases: PubMed, EMBASE, Cochrane Library, Web of Science, CNKI database, VIP database and Wanfang database. We included randomized controlled trials in this meta-analysis to evaluate the difference in mean changes in left ventricular echocardiographic parameters between the treatment and control groups. Results: The results of meta-analysis showed that LAVI (WMD = −6.29, 95%CI (−10, −2.58), P &lt; 0.001), E/e′ (WMD = −2.15, 95%CI (−4.08, −0.21), P = 0.003), LVEF (WMD = 3.67, 95%CI (0.59, 6.75), P = 0.02), LVEDV (WMD = −1.99, 95%CI (−26.49, −22.50), P = 0.87), LVESV (WMD = −8.36, 95%CI (−17.36, −0.65), P = 0.07). Conclusions: Empagliflozin can significantly reduce the LAVI and E/e′ of patients with Type 2 diabetes. It can improve cardiac function of patients. 
  
 
</p></abstract><kwd-group><kwd>恩格列净，2型糖尿病，左心室重构, Empagliflozin</kwd><kwd> Type 2 Diabetes</kwd><kwd> Left Ventricular Remodeling</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨恩格列净对改善2型糖尿病(T2DM)患者左心室重构的疗效。方法：我们在PubMed、EMBASE、Cochrane Library、Web of Science、CNKI数据库、VIP数据库、Wanfang数据库，共7个电子数据库中搜索了在2020年9月30日之前发表的文章，包括中文和英文。我们在分析中纳入了随机对照试验。评价治疗组与对照组左室超声心动图参数平均变化的差异。结果：Meta分析结果显示，LAVI (WMD = −6.29, 95%CI (−10, −2.58)，P &lt; 0.001), E/e′ (WMD = −2.15, 95%CI (−4.08, −0.21), P = 0.003), LVEF (WMD = 3.67, 95%CI (0.59, 6.75), P = 0.02), LVEDV (WMD = −1.99, 95%CI (−26.49, −22.50), P = 0.87), LVESV (WMD = −8.36, 95%CI (−17.36, −0.65), P = 0.07)。结论：恩格列净可显著降低2型糖尿病患者的LAVI和E/e′，改善患者心功能。</p></sec><sec id="s2"><title>关键词</title><p>恩格列净，2型糖尿病，左心室重构</p></sec><sec id="s3"><title>Empagliflozin in Patients with Type 2 Diabetes: A Meta-Analysis of Cardiovascular Remodeling</title><p>Zhenfei Ou, Ling Shang, Hailing Xu, Xuejuan Zhang</p><p>Department of Family Medicine, Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p>Received: Jan. 7<sup>th</sup>, 2021; accepted: Jan. 29<sup>th</sup>, 2021; published: Feb. 9<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/6-1571883x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: The purpose of this meta-analysis is to explore the efficacy of empagliflozin in improving left ventricular (LV) remodeling in patients with type 2 diabetes (T2DM). Methods: We searched articles published before September 30, 2020, Language including Chinese and English, in 7 electronic databases: PubMed, EMBASE, Cochrane Library, Web of Science, CNKI database, VIP database and Wanfang database. We included randomized controlled trials in this meta-analysis to evaluate the difference in mean changes in left ventricular echocardiographic parameters between the treatment and control groups. Results: The results of meta-analysis showed that LAVI (WMD = −6.29, 95%CI (−10, −2.58), P &lt; 0.001), E/e′ (WMD = −2.15, 95%CI (−4.08, −0.21), P = 0.003), LVEF (WMD = 3.67, 95%CI (0.59, 6.75), P = 0.02), LVEDV (WMD = −1.99, 95%CI (−26.49, −22.50), P = 0.87), LVESV (WMD = −8.36, 95%CI (−17.36, −0.65), P = 0.07). Conclusions: Empagliflozin can significantly reduce the LAVI and E/e′ of patients with Type 2 diabetes. It can improve cardiac function of patients.</p><p>Keywords:Empagliflozin, Type 2 Diabetes, Left Ventricular Remodeling</p><disp-formula id="hanspub.40341-formula25"><graphic xlink:href="//html.hanspub.org/file/6-1571883x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/6-1571883x7_hanspub.png" /> <img src="//html.hanspub.org/file/6-1571883x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>目前全球糖尿病患者3.82亿，在2035年将会增加到5.92亿，其中90%是2型糖尿病患者 [<xref ref-type="bibr" rid="hanspub.40341-ref1">1</xref>]，糖尿病患者较非糖尿病患者心血管风险增加2倍，更加容易发生左室的功能障碍和心力衰竭 [<xref ref-type="bibr" rid="hanspub.40341-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.40341-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.40341-ref4">4</xref>]，但是强化降糖并不会降低心血管风险 [<xref ref-type="bibr" rid="hanspub.40341-ref5">5</xref>]，直到SGLT2抑制剂的问世，打破这一僵局。针对2型糖尿病患者进行的大型心血管试验结果表明，钠–葡萄糖协同转运体2 (SGLT2)抑制剂可以改善心血管预后，特别是可以降低因心力衰竭住院的风险 [<xref ref-type="bibr" rid="hanspub.40341-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.40341-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.40341-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.40341-ref9">9</xref>]。</p><p>目前治疗心力衰竭的药物主要有利尿剂、血管紧张素转换酶抑制剂(angiotensin converting enzyme inhibitor)/血管紧张素II受体拮抗剂(Angiotensin II receptor antagonist)、β受体阻滞剂、沙库巴曲缬沙坦、醛固酮受体拮抗剂、地高辛等 [<xref ref-type="bibr" rid="hanspub.40341-ref10">10</xref>]。而SGLT2抑制剂是通过特异性地抑制肾近端小管对葡萄糖的重吸收来降低血糖水平，近期研究提示其对心脏获益。已有多项临床研究关于SGLT2抑制剂对心室结构和功能的影响，虽然提出了许多假设，但其减少心衰患者住院的机制仍不确定，心功能的影响存在争议，左心室质量指数(LVMI)是心肌梗死、心力衰竭住院率和死亡率等心血管事件的独立预测因子 [<xref ref-type="bibr" rid="hanspub.40341-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.40341-ref12">12</xref>]。因此我们对心功能的随机对照试验进行了meta分析，以评估恩格列净对2型糖尿病患者的心脏重构的作用。经查询，目前尚无我国开展的恩格列净在心功能相关的随机对照临床试验。本研究基于已上市产品在国外完成的相关研究结果进行Meta分析。分析此药物在心脏重构的作用，为药物作用机制提供数据支持。</p></sec><sec id="s6"><title>2. 方法</title><sec id="s6_1"><title>2.1. 数据来源</title><p>PubMed、EMBASE、Cochrane图书馆、Web of Science、CNKI数据库、VIP数据库和万方数据库对2010年至2020年9月30日发表的研究进行了完整的文献检索，中文检索策略为“临床试验或随机对照试验”与“2型糖尿病”与“心室或心房”与“恩格列净”。英文检索策略为“Type 2 diabetes OR Type 2 Diabetes”AND“randomized controlled OR randomized clinical OR controlled clinical trials”AND“empagliflozin”AND“ventricular OR atrial OR heart”。根据纳入和排除标准筛选243篇关于恩格列净治疗2型糖尿病的文献，最后纳入2篇文献进行荟萃分析。</p></sec><sec id="s6_2"><title>2.2. 纳入标准</title><p>① 文献资料均为随机临床试验(randomized clinicaltrial, RCTs)，无论是否采用分配隐藏或盲法，语种包括英文和中文；② 内容涉及恩格列净对2型糖尿病患者心功能影响；③ 试验组患者给予恩格列净；对照组患者给予安慰剂；④ 至少有四个超声心动图结果被报道。</p></sec><sec id="s6_3"><title>2.3. 排除标准</title><p>① 观察性研究；② 动物研究、综述、指南；③ 其他新药干预研究；④ 文献应用的结果指标无法提取或计算；⑤ 文献发表的重复数据。</p></sec><sec id="s6_4"><title>2.4. 质量控制</title><p>两名研究人员独立筛选了文献，并严格按照纳入和排除标准检查选定的研究。如果不同意某项研究，则征求第三位研究者的意见，以完成选定的研究项目。文档筛选流程图(见图1)。两位研究人员共同提取了每项纳入研究的数据，包括(第一作者，发表时间，研究方法，研究对象，平均年龄，治疗时间，评估指标)，然后提取了包括基线数据和干预后数据在内的各种分类指标(见表1)。我们选择了直接反映心脏结构变化的指标包括左室射血分数(LVEF)，左室收缩末容积(LVESV)，左室舒张末容积(LVEDV)，左心房容积指数(LAVI)和舒张早期二尖瓣血流速度与舒张早期二尖瓣环运动速度(E/e′)。</p></sec><sec id="s6_5"><title>2.5. 统计方法</title><p>应用Cochrane.com提供的RevMan 5.3软件。对于连续变量，将加权均数差(WMD)和95% (CI)用作功效分析统计数据；计数数据以相对风险(RR)及其95%置信区间CI表示。I<sup>2</sup>测试和Q测试用于评估异质性。P ≤ 0.10或者I<sup>2</sup> ≥ 50%表明研究之间存在统计异质性，并使用随机效应模型进行分析；否则，使用固定效应模型进行分析；Stata 14.0软件用于敏感性分析，以评估研究结果的稳定性。P &lt; 0.05表示差异具有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><p>1) 治疗后2项研究的LVEF水平在研究之间无统计学差异(P = 0.026, I<sup>2</sup> = 21%)，并使用固定效应模型。荟萃分析表明，两组患者治疗后LEVF水平较前显著升高，差异具有统计学意义[WMD = 3.67, 95%CI (0.59, 6.75), P = 0.02] (见图2)。</p><p>2) 治疗后2项研究的LAVI水平显示研究之间没有统计学异质性(P = 0.46, I<sup>2</sup> = 0%)，并使用了固定效应模型。荟萃分析表明，两组患者的LAVI水平在治疗后均显著降低，差异具有统计学意义[WMD = −6.29, 95%CI (−10, −2.58), P &lt; 0.001] (见图3)。</p><p>图1. 文献筛选流程图</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Overview of main characteristics of the two trial populations at baselin</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >Nick S. R. Lan 2020</th><th align="center" valign="middle"  colspan="2"  >Subodh Verma 2019</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Empagliflozin</td><td align="center" valign="middle" >Placebo</td><td align="center" valign="middle" >Empagliflozin</td><td align="center" valign="middle" >Placebo</td></tr><tr><td align="center" valign="middle" >Age (years)</td><td align="center" valign="middle" >60.8 &#177; 9.5</td><td align="center" valign="middle" >65.1 &#177; 10.4</td><td align="center" valign="middle" >64</td><td align="center" valign="middle" >64</td></tr><tr><td align="center" valign="middle" >Male gender</td><td align="center" valign="middle" >19 (86.4)</td><td align="center" valign="middle" >15 (68.2)</td><td align="center" valign="middle" >44 (90)</td><td align="center" valign="middle" >46 (96)</td></tr><tr><td align="center" valign="middle" >Duration of T2DM, median (IQR), y</td><td align="center" valign="middle" >5.5 (4~12.25)</td><td align="center" valign="middle" >8 (4~19.5)</td><td align="center" valign="middle" >10.0 (4.0, 15.0)</td><td align="center" valign="middle" >10.0 (5.0, 15.0)</td></tr><tr><td align="center" valign="middle" >NT-pro BNP, pg/mL</td><td align="center" valign="middle" >297 (128~1497.5)</td><td align="center" valign="middle" >262.5 (122~806)</td><td align="center" valign="middle" >97 (46, 188)</td><td align="center" valign="middle" >116 (62, 227)</td></tr><tr><td align="center" valign="middle"  colspan="5"  >medications</td></tr><tr><td align="center" valign="middle" >ACE inhibitor</td><td align="center" valign="middle" >22 (100)</td><td align="center" valign="middle" >21 (95.5)</td><td align="center" valign="middle" >40 (82)</td><td align="center" valign="middle" >41 (85)</td></tr></tbody></table></table-wrap><p>表1. 基线时两个试验人群的主要特征</p><p>图2. 两组患者治疗后LVEF水平的Meta分析森林图</p><p>图3. 两组患者治疗后LAVI水平的Meta分析森林图</p><p>3) 治疗后2项研究的E/e′水平提示没有统计学异质性(P = 0.29, I<sup>2</sup> = 12%)，使用固定效应模型。Meta分析表明，两组患者的E/e′水平在治疗后显著降低，差异具有统计学意义[WMD = −2.15, 95%CI (−4.08, −0.21), P = 0.003] (见图4)。</p><p>4) 因为治疗后2项研究的治疗后LVEDV水平无统计学差异(P = 0.06, I<sup>2</sup> = 73%)，所以采用了随机模型。荟萃分析表明，治疗后的LVEDV水平较前无统计学差异[WMD = −1.99, 95%CI (−26.49, −22.50), P = 0.87] (见图5)。</p><p>图4. 两组患者治疗后E/e′水平的Meta分析森林图</p><p>图5. 两组患者治疗后LVEDV水平的Meta分析森林图</p><p>5) 在治疗后2项研究的LVESV水平在研究之间无统计学差异(P = 0.06, I<sup>2</sup> = 73%)，并使用固定模型。荟萃分析提示，两组患者治疗后的LVESV水平无统计学差异[WMD = −8.36, 95%CI (−17.36, −0.65), P = 0.07] (见图6)。</p><p>图6. 两组患者治疗后LVESV水平的Meta分析森林图</p></sec><sec id="s8"><title>4. 讨论</title><p>SGLT2抑制剂可以降低心衰患者住院率，但是不影响动脉粥样硬化相关事件，主要机制可能与左室功能改善有关 [<xref ref-type="bibr" rid="hanspub.40341-ref13">13</xref>]。目前药理机制考虑主要有：(1) 肾脏的排钠、排糖、利尿、降低肾小球毛细血管血压作用 [<xref ref-type="bibr" rid="hanspub.40341-ref14">14</xref>] (2) 心脏的增加供氧，改善能量代谢，降低心肌纤维化，减少心外膜脂肪沉积作用 (3) 血管内皮功能的改善，降低血管阻力，降低大动脉壁强度作用 (4) 影响心脏的神经激素途径，降低交感神经系统的激活 [<xref ref-type="bibr" rid="hanspub.40341-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.40341-ref16">16</xref>]，以上机制通过降低心脏前后负荷，改善胰岛素抵抗，影响心脏重构 [<xref ref-type="bibr" rid="hanspub.40341-ref17">17</xref>]。</p><p>目前部分非随机对照试验研究证实SGLT2抑制剂在治疗糖尿病患者3至6个月后可降低左室质量指数和改善舒张功能，这些药物包括恩格列净(empagliflozin) [<xref ref-type="bibr" rid="hanspub.40341-ref18">18</xref>]、坎格列净(canagliflozin) [<xref ref-type="bibr" rid="hanspub.40341-ref19">19</xref>]、达格列净(dapagliflozin) [<xref ref-type="bibr" rid="hanspub.40341-ref20">20</xref>]、鲁格列净和托格列净(tofogliflozin) [<xref ref-type="bibr" rid="hanspub.40341-ref21">21</xref>]。但这些研究纳入人群有限，随访时间短。同时有研究提示托格列净在2型糖尿病患者中的使用，并没有明显改善左室收缩或舒张功能 [<xref ref-type="bibr" rid="hanspub.40341-ref22">22</xref>]。本研究荟萃分析提示恩格列净能够显著改善2型糖尿病患者的心脏重构，治疗后E/e′、LAVI水平显著下降，LVEF水平显著上升，但治疗后LVEDV、LVESV水平方面均无显著差异，这提示恩格列净可能会为患者带来短期心脏获益，但是否能改善其远期预后，仍需进一步探讨。</p><p>本研究存在局限性(1) 文献的研究时间少于25周，药物远期预后研究相对较少。(2) 纳入的研究个体数量有限，并且部分研究病例数较少，对于纳入2型糖尿病患者的疾病严重程度、患病时间、是否合并其他疾病有差异，可能导致结果存在一定的异质性。(3) 由于阳性结果的文献更易发表，本系统评价仅纳入了中文和英文文献，可能会存在一定的系统误差。由此可见，本研究所得结论仍需要更多大样本、高质量的RCT进一步证实。</p><p>综上所述，恩格列净可以改善心脏重构，迄今为止，对患有糖尿病的动物和人类的研究表明，SGLT2抑制剂可以潜在地改善左室质量指数和左室舒张功能。但是SGLT2抑制剂对心脏结构和功能的具体生物学作用仍然不确定，需要更多RCTs研究支持。</p></sec><sec id="s9"><title>文章引用</title><p>欧振飞,商 玲,徐海凌,张雪娟. 恩格列净治疗2型糖尿病患者心脏重构的Meta分析Empagliflozin in Patients with Type 2 Diabetes: A Meta-Analysis of Cardiovascular Remodeling[J]. 临床医学进展, 2021, 11(02): 469-475. https://doi.org/10.12677/ACM.2021.112067</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40341-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">International Diabetes Federation (2013) IDF Diabets Atlas. 6th Edition, International Diabetes Federation, Brussels.</mixed-citation></ref><ref id="hanspub.40341-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Di Angelantonio, E., Kaptoge, S., Wormser, D., Willeit, P., et al. (2015) Association of Cardiometabolic Multimorbidity with Mortality. JAMA, 314, 52-60. &lt;br&gt;https://doi.org/10.1001/jama.2015.7008</mixed-citation></ref><ref id="hanspub.40341-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">From, A.M., Scott, C.G. and Chen, H.H. (2010) The Development of Heart Failure in Patients with Diabetes Mellitus and Pre-Clinical Diastolic Dysfunction a Population-Based Study. Journal of the American College of Cardiology, 55, 300-305. &lt;br&gt;https://doi.org/10.1016/j.jacc.2009.12.003</mixed-citation></ref><ref id="hanspub.40341-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Dawson, A., Morris, A.D. and Struthers, A.D. (2005) The Epidemiology of Left Ventricular Hypertrophy in Type 2 Diabetes Mellitus. Diabetologia, 48, 1971-1979. &lt;br&gt;https://doi.org/10.1007/s00125-005-1896-y</mixed-citation></ref><ref id="hanspub.40341-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Stratton, I.M., Adler, A.I., Neil, H.A., Matthews, D.R., Manley, S.E., Cull, C.A., et al. (2000) Association of Glycaemia  with Macrovascular and Microvascular Complications of Type 2 Diabetes (UKPDS 35): Prospective Observational Study. BMJ, 321, 405-412. &lt;br&gt;https://doi.org/10.1136/bmj.321.7258.405</mixed-citation></ref><ref id="hanspub.40341-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondu, N., et al. (2017) Canagliflozin Andcardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine, 377, 644-657. 
&lt;br&gt;https://doi.org/10.1056/NEJMoa1611925</mixed-citation></ref><ref id="hanspub.40341-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Wiviott, S.D., Raz, I., Bonaca, M.P., Mosenzon, O., Kato, E.T., Cahn, A., et al. (2019) Dapagliflozin and Cardiovascularoutcomes in Type 2 Diabetes. New England Journal of Medicine, 380, 347-357. 
&lt;br&gt;https://doi.org/10.1056/NEJMoa1812389</mixed-citation></ref><ref id="hanspub.40341-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Perkovic, V., Jardine, M.J., Neal, B., Bompoint, S., Heerspink, H.J.L., Charytan, D.M., et al. (2019) Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 380, 2295-306. 
&lt;br&gt;https://doi.org/10.1056/NEJMoa1811744</mixed-citation></ref><ref id="hanspub.40341-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 373, 2117-2128. 
&lt;br&gt;https://doi.org/10.1056/NEJMoa1504720</mixed-citation></ref><ref id="hanspub.40341-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018 [J] .中华心血管病杂志, 2018, 46(10): 760-789.</mixed-citation></ref><ref id="hanspub.40341-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Abdi-Ali, A., Miller, R.J.H., Southern, D., Zhang, M., Mikami, Y., Knudtson, M., et al. (2018) LV Mass Independently Predicts Mortality and Need for Future Revascularization in Patients Undergoing Diagnostic Coronary Angiography. JACC: Cardiovascular Imaging, 11, 423-433. &lt;br&gt;https://doi.org/10.1016/j.jcmg.2017.04.012</mixed-citation></ref><ref id="hanspub.40341-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Mathew, J., Sleight, P., Lonn, E., Johnstone, D., Pogue, J., Yi, Q.L., et al. (2001) Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitorramipril. Circulation, 104, 1615-1621. &lt;br&gt;https://doi.org/10.1161/hc3901.096700</mixed-citation></ref><ref id="hanspub.40341-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Sattar, N., McLaren, J., Kristensen, S.L., Preiss, D. and McMurray, J.J. (2016) SGLT2 Inhibitionand Cardiovascular Events: Why did EMPA-REG Outcomes Surprise and What Were the Likely Mechanisms? Diabetologia, 59, 1333-1339.  
&lt;br&gt;https://doi.org/10.1007/s00125-016-3956-x</mixed-citation></ref><ref id="hanspub.40341-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Shubrook, J.H., Bokaie, B.B. and Adkins, S.E. (2015) Empagliflozin in the Treatment of Type 2 Diabetes: Evidence to Date. Drug Design, Development and Therapy, 9, 5793-5803. &lt;br&gt;https://doi.org/10.2147/DDDT.S69926</mixed-citation></ref><ref id="hanspub.40341-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Chilton, R., Tikkanen, I., Cannon, C.P., Crowe, S. Woerle, H.J., Broedl, U.C., et al. (2015) Effects of Empagliflozin on Blood Pressure and Markers of Arterial Stiffness and Vascular Resistance in patients with Type 2 Diabetes. Diabetes, Obesity and Metabolism, 17, 1180-1193. &lt;br&gt;https://doi.org/10.1111/dom.12572</mixed-citation></ref><ref id="hanspub.40341-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Sano, M. (2018) A New Class of Drugs for Heart Failure: SGLT2 Inhibitors Reduce Sympathetic Overactivity. Journal of Cardiology, 71, 471-476. &lt;br&gt;https://doi.org/10.1016/j.jjcc.2017.12.004</mixed-citation></ref><ref id="hanspub.40341-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Brown, A.J.M., Lang, C., McCrimmon, R. and Struthers, A. (2017) Does Dapagliflozin Regress Left Ventricularhypertrophy in Patients with Type 2 Diabetes? A Prospective, Double-Blind, Randomised, Placebo-Controlled Study. BMC Cardiovascular Disorders, 17, Article No. 229. &lt;br&gt;https://doi.org/10.1186/s12872-017-0663-6</mixed-citation></ref><ref id="hanspub.40341-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Verma, S., Garg, A., Yan, A.T., Gupta, A.K., Al-Omran, M., Sabongui, A., et al. (2016) Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals with Diabetes: An Important Clue to the EMPA- REGOUTCOME Trial? Diabetes Care, 39, e212-e213. &lt;br&gt;https://doi.org/10.2337/dc16-1312</mixed-citation></ref><ref id="hanspub.40341-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Matsutani, D., Sakamoto, M., Kayama, Y., Takeda, N., Horiuchi, R. and Utsunomiya, K. (2018) Effect of Canagliflozin on Left Ventricular Diastolic Function in Patients with Type 2 Diabetes. Cardiovascular Diabetology, 17, Article No. 73. &lt;br&gt;https://doi.org/10.1186/s12933-018-0717-9</mixed-citation></ref><ref id="hanspub.40341-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Soga, F., Tanaka, H., Tatsumi, K., Mochizuki, Y., Sano, H., Toki, H., Matsumoto, K., et al. (2018) Impact of Dapagliflozin on Left Ventricular Diastolicfunction of Patients with Type 2 Diabetic Mellitus with Chronic Heart Failure. Cardiovascular Diabetology, 17, Article No.132. &lt;br&gt;https://doi.org/10.1186/s12933-018-0775-z</mixed-citation></ref><ref id="hanspub.40341-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Sakai, T. and Miura, S. (2018) Abstract 17041: Effectof Sodium-Glucose Cotransporter 2 Inhibitor on Vascular Endothelial Function and Diastolic Function in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF). Circulation, 136, Article ID: A17041.</mixed-citation></ref><ref id="hanspub.40341-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Tochiya, M., Makino, H., Tamanaha, T., Matsuo, M., Hishida, A., Koezuka, R., et al. (2020) Effect of Tofogliflozin on Cardiac and Vascular Endothelial Function in Patients with Type 2 Diabetes and Heart Diseases: A Pilot Study. Journal of Diabetes Investigation, 11, 400-404. &lt;br&gt;https://doi.org/10.1111/jdi.13122</mixed-citation></ref></ref-list></back></article>